This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Thu May 23, 2013 2:53 pm


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 4 posts ] 
Author Message
PostPosted: Fri Feb 17, 2012 3:52 am 
Offline
Family Elder
User avatar

Joined: Wed Oct 14, 2009 3:00 pm
Posts: 1688
Inflammation in brain inhibited by new class of potential drugs

Image


Scientists at Emory University School of Medicine have identified a new group of compounds that may protect brain cells from inflammation linked to seizures and neurodegenerative diseases.

The compounds block signals from EP2, one of the four receptors for prostaglandin E2, which is a hormone involved in processes such as fever, childbirth, digestion and blood pressure regulation. Chemicals that could selectively block EP2 were not previously available. In animals, the EP2 blockers could markedly reduce the injury to the brain induced after a prolonged seizure, the researchers showed.

The results were published online this week in the Proceedings of the National Academy of Sciences Early Edition....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/3349

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis


Top
 Profile  
 
PostPosted: Fri Feb 17, 2012 2:29 pm 
Offline
Family Member
User avatar

Joined: Sat Dec 08, 2007 4:00 pm
Posts: 89
squiffy2 wrote:
Inflammation in brain inhibited by new class of potential drugs

Image


Scientists at Emory University School of Medicine have identified a new group of compounds that may protect brain cells from inflammation linked to seizures and neurodegenerative diseases.

The compounds block signals from EP2, one of the four receptors for prostaglandin E2, which is a hormone involved in processes such as fever, childbirth, digestion and blood pressure regulation. Chemicals that could selectively block EP2 were not previously available. In animals, the EP2 blockers could markedly reduce the injury to the brain induced after a prolonged seizure, the researchers showed.

The results were published online this week in the Proceedings of the National Academy of Sciences Early Edition....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/3349


Squiffy, i didn't see the name of the compound that they used as did i miss it in your posted article?

I'd like to post this story over at an ALS forum that i visit daily.


Top
 Profile  
 
PostPosted: Fri Feb 17, 2012 2:43 pm 
Offline
Family Elder
User avatar

Joined: Mon Sep 10, 2007 3:00 pm
Posts: 4680
Location: southern California
Here you go, Harry--the full article does not name the compounds they have tested, so I did some more research for you.
Here's the actual journal publication:
http://www.pnas.org/content/early/2012/02/07/1120195109

Here's the abstract---this is all being done in mouse models right now, and is very far away from clinical applications-

Quote:
With interest waning in the use of cyclooxygenase-2 (COX-2) inhibitors for inflammatory disease, prostaglandin receptors provide alternative targets for the treatment of COX-2–mediated pathological conditions in both the periphery and the central nervous system. Activation of prostaglandin E2 receptor (PGE2) subtype EP2 promotes inflammation and is just beginning to be explored as a therapeutic target. To better understand physiological and pathological functions of the prostaglandin EP2 receptor, we developed a suite of small molecules with a 3-aryl-acrylamide scaffold as selective EP2 antagonists. The 12 most potent compounds displayed competitive antagonism of the human EP2 receptor with KB 2–20 nM in Schild regression analysis and 268- to 4,730-fold selectivity over the prostaglandin EP4 receptor. A brain-permeant compound completely suppressed the up-regulation of COX-2 mRNA in rat cultured microglia by EP2 activation and significantly reduced neuronal injury in hippocampus when administered in mice beginning 1 h after termination of pilocarpine-induced status epilepticus. The salutary actions of this novel group of antagonists raise the possibility that selective block of EP2 signaling via small molecules can be an innovative therapeutic strategy for inflammation-related brain injury.


Here's a link to a more lay person friendly article:
http://www.sciencedaily.com/releases/20 ... 122031.htm

cheer

_________________
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
dual stents placed 5/09
CCSVI in MS


Top
 Profile  
 
PostPosted: Fri Feb 17, 2012 3:54 pm 
Offline
Family Member
User avatar

Joined: Sat Dec 08, 2007 4:00 pm
Posts: 89
cheerleader wrote:
Here you go, Harry--the full article does not name the compounds they have tested, so I did some more research for you.
Here's the actual journal publication:
http://www.pnas.org/content/early/2012/02/07/1120195109

Here's the abstract---this is all being done in mouse models right now, and is very far away from clinical applications-

Quote:
With interest waning in the use of cyclooxygenase-2 (COX-2) inhibitors for inflammatory disease, prostaglandin receptors provide alternative targets for the treatment of COX-2–mediated pathological conditions in both the periphery and the central nervous system. Activation of prostaglandin E2 receptor (PGE2) subtype EP2 promotes inflammation and is just beginning to be explored as a therapeutic target. To better understand physiological and pathological functions of the prostaglandin EP2 receptor, we developed a suite of small molecules with a 3-aryl-acrylamide scaffold as selective EP2 antagonists. The 12 most potent compounds displayed competitive antagonism of the human EP2 receptor with KB 2–20 nM in Schild regression analysis and 268- to 4,730-fold selectivity over the prostaglandin EP4 receptor. A brain-permeant compound completely suppressed the up-regulation of COX-2 mRNA in rat cultured microglia by EP2 activation and significantly reduced neuronal injury in hippocampus when administered in mice beginning 1 h after termination of pilocarpine-induced status epilepticus. The salutary actions of this novel group of antagonists raise the possibility that selective block of EP2 signaling via small molecules can be an innovative therapeutic strategy for inflammation-related brain injury.


Here's a link to a more lay person friendly article:
http://www.sciencedaily.com/releases/20 ... 122031.htm

cheer


Thank you very much Cheerleader and i really do appreciate you taking the time to research this some more as that's really nice of you to do :-D and i'll post your pnas.org link over at the ALS forum.

harry


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 4 posts ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. Neuronal Damage in Brain Inflammation

Lyon

0

1060

Thu Mar 01, 2007 4:25 pm

Lyon View the latest post

There are no new unread posts for this topic. Sex hormone precursor inhibits brain inflammation

dignan

0

793

Thu May 12, 2011 2:14 pm

dignan View the latest post

There are no new unread posts for this topic. Nose-to-brain administration of drugs

[ Go to pageGo to page: 1, 2 ]

thinkingoutloud86

24

3996

Sat Feb 09, 2008 5:43 pm

Jim_P View the latest post

There are no new unread posts for this topic. Breakthrough in delivering drugs to the brain

squiffy2

0

732

Mon Mar 21, 2011 11:56 pm

squiffy2 View the latest post

There are no new unread posts for this topic. Class Action Lawsuit for CCSVI

JimDav

13

1714

Sat May 08, 2010 3:22 am

AMcG View the latest post

 


Who is online

Users browsing this forum: No registered users


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: